Fallypride

Summary

Fallypride (CHEMBL392158) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including obesity disorder and morbid obesity.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 364.5 Da · C20H29FN2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL392158
Name	Fallypride
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10021692
Molecular formula	C20H29FN2O3
Molecular weight	364.5
InChIKey	OABRYNHZQBZDMG-INIZCTEOSA-N

SMILES: COC1=CC(=CC(=C1OC)C(=O)NC[C@@H]2CCCN2CC=C)CCCF

IUPAC name: 5-(3-fluoropropyl)-2,3-dimethoxy-N-[[(2S)-1-prop-2-enylpyrrolidin-2-yl]methyl]benzamide

Also known as: Fallypride, FALLYPRIDE

Patent coverage: 41 distinct patent families (83 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: D(2) dopamine receptor, D(4) dopamine receptor, D(3) dopamine receptor, D(1A) dopamine receptor.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD2	10.7	Ki	0.02	nM	CHEMBL_ACT_26187230
DRD2	10.01	Ki	0.1	nM	CHEMBL_ACT_14672743
DRD3	9.72	Ki	0.19	nM	CHEMBL_ACT_26187229
DRD3	8.8	Ki	1.6	nM	CHEMBL_ACT_2042903
DRD3	8.77	IC50	1.7	nM	CHEMBL_ACT_26187231
DRD2	8.68	Ki	2.1	nM	CHEMBL_ACT_2042901
DRD2	8.66	Ki	2.2	nM	CHEMBL_ACT_2042902
DRD2	8.3	IC50	5	nM	CHEMBL_ACT_2227393
DRD4	5.89	Ki	1300	nM	CHEMBL_ACT_2042904

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obesity disorder	2	MONDO:0011122	EFO:0001073
morbid obesity	1	MONDO:0005139	EFO:0001074

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02310360	Not specified	ACTIVE_NOT_RECRUITING	Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).